Skystar Bio-Pharmaceutical (SKBI) Reports 33% Growth in Revenue From Continuing Operations
XI’AN, CHINA–(Marketwire – 08/17/10) – Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI – News) (“Skystar” or the “Company”), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited second quarter fiscal year 2010 earnings, for the period ended June 30, 2010.
Second Quarter 2010 Highlights
- Revenue increases 33% YoY to $8.3 million
- Veterinary vaccines totaled $0.4 million, up 21% YoY
- Veterinary medicines totaled $5.5 million, up 41% YoY
- Feed additives totaled $0.4 million, up 31% YoY
- Micro-organism products totaled $2.0 million, up 14% YoY
- Gross margin of 53% for the second quarter of fiscal 2010 as compared to 53% in the year ago period
- GAAP net income of $2.4 million or $0.33 per fully diluted share, compared with a loss of $0.1 million or ($0.03) per fully diluted share in the year ago period
- Fiscal 2010 top line revenue guidance range remains at $45.5 million to $47.5 million
First Half 2010 Financial Highlights
- First half fiscal 2010 revenue increases 30% YoY to 13.1 million
- Gross margin of 53% for the first half of fiscal 2010 as compared to 51% in the year ago period
- GAAP net income of $3.5 million or $0.49 per fully diluted share, compared with GAAP net income of $0.9 million or $0.25 per fully diluted share in the year ago period
Mr. Weibing Lu, Skystar Bio-Pharmaceutical’s chairman and chief executive officer, commented, “Skystar’s performance in the second quarter of fiscal 2010 positions the Company well for the second half of the fiscal year which is seasonally our strongest half. The second quarter’s performance can be attributed to improved sales effort and increased utilization of production capacity at our Huxian plant, including the expanded micro-organism facility completed in 2009 and came online in June of this year, as well as increased product variety. We currently produce over 248 products as compared to over 195 products in the first quarter of 2010.
“Overall outlook for the industry remains promising despite severe flood damage in many of the agricultural regions of China. The Company anticipates meeting its financial goals and metrics for the year. During the quarter, the Company filed an S-1 registration which was subsequently withdrawn. The intention was not to raise capital at any price or level of dilution to shareholders but in preparation of strengthening our balance sheet should an opportunistic moment arise. The Company does not intend to raise capital at current price levels and is looking into alternative sources of funding such as low interest debt at the local level. Our current income from operations and cash on hand are at adequate levels to maintain daily operations.
“Skystar is committed to continue its efforts to expand manufacturing capacity to meet market demands for our products. In addition, the Company has negotiated with some of our raw material suppliers to receive favorable pricing while obtaining the necessary materials to supply seasonal production ramp up in the third quarter. Subsequently, we have lowered our cash advances to suppliers as compared to the same period last year, improving our cash flow position and will continue to manage this process closely.
“In preparation for the fiscal third quarter, historically the Company’s strongest quarter, the Company build up the inventory levels in anticipation of the upcoming demand. Accounts receivable and inventories increased significantly in the second quarter as part of the Company’s strategy to expand market share. Historically, we have collected nearly all of our accounts receivable, and management expects our collection rate to normalize in the third quarter. To be prudent, however, we have made provisions by increasing our allowance for bad debt.
“R&D for the period has decreased relative to the prior year as projects have entered late stage developments and required less cash outlays. General and administrative expenses for our Chinese operating entity have increased with expanded operations and added acquisition related expenses, plus increased allowance for accounts receivable.
“With regard to Skystar’s construction projects, the construction of the vaccine facility at our Huxian plant was completed as of June 30, 2010. We expect to release a thorough update to shareholders regarding the facility shortly.
“We expect our sales and growth trajectory to continue through the remainder of the year as we reiterate fiscal guidance for the full year. The Company is positioning itself to be able to meet anticipated market demand for its products, and have sufficient cash resources on hand to maintain on-going operations. We hope to continue to maximize the Company’s performance for our shareholders,” concluded Mr. Lu.
Financial Summary
Gross profit for second quarter 2010 was $4.4 million, up 33% from second quarter 2009. Gross margin for the period was 53%, in line with historical year over year comparables.
Operating expenses for second quarter 2010 were $1.6 million, or 20% of total revenue, compared with $1.6 million or 25% of total revenue in the year ago period. Increased G&A expenses were offset by declines in R&D and selling expenses resulting in a slight increase in total operating expenses. Total operating expense increased 3% year over year.
Research and development (R&D) costs were $0.19 million, or less than 3% of revenue in the second quarter 2010, down from $0.3 million, or 6% of revenue during second quarter 2009. Most of the company’s existing research projects were in the later phases, and required less cash outlays as compared to the early stages of the projects in the same period last year where we had large scale testing and clinical trials.
Selling expenses totaled $0.4 million, or 5% of revenue, for the second quarter 2010, compared with $0.6 million, or 9% of revenue, in the second quarter 2009. General and administrative expenses were $1.0 million, or 12% of revenue, in second quarter 2010, compared with $0.6 million, or 10% of revenue, in second quarter 2009. General and administrative expenses have increased due to acquisition related costs and costs related to the expansion of existing operations, and the increased allowance for accounts receivable.
Operating income increased by 60% year over year to $2.7 million in the second quarter of fiscal year 2010, compared with $1.7 million in the same quarter a year ago, and operating margin increased to 33% from 27% in the same period a year ago.
Net income for the second quarter of 2010 was $2.45 million, or $0.33 per fully diluted share. This compares to a net loss of $0.1 million or a loss of $0.03 per fully diluted share in the same quarter of 2009. Skystar’s adjusted net income for the second quarter of 2010 was $2.2 million, or $0.31 per fully diluted share, compared with $1.36 million, or $0.36 per fully diluted share, in the second quarter of 2009 (See “About Non-GAAP Financial Measures” toward the end of this release.)
As of June 30, 2010, Skystar had approximately $3.5 million in cash and restricted cash, current assets of $29.4 million and current liabilities of $5.0 million.
China Floods
On July 21, 2010, Xinhua news agency, reported China’s worst flood in over a decade, displacing over 110 million people and affecting over 17 million acres of farmland. Additionally, as reported by Xinhua news agency on August 6, 2010, China’s Ministry of Agriculture urged local authorities to resume agricultural production as soon as possible and create favorable conditions for the fall harvest.
To date Skystar’s business lines have not been affected by the acts of nature; however, the Company will closely monitor the situation and react accordingly.
Fiscal 2010 Guidance
Taking into consideration the vast flooding and severity of the conditions across China’s farming communities and any potential impact on the Company’s business, we are taking a conservative approach and will maintain current guidance of $45.5 million to $47.5 million for the full fiscal 2010 year. We will re-evaluate the situation as visibility improves.
Conference Call & Webcast Information
Skystar will host a conference call at 8:00 a.m. ET on Tuesday, August 17, 2010 to review the Company’s second quarter financial and operational performance. Mr. Weibing Lu, Skystar Bio-Pharmaceutical chairman and chief executive officer, will host the call, which will be webcast live.
The webcast will be made available on the investor relations section of the Skystar corporate website at http://www.skystarbio-pharmaceutical.com. Telephone access to the conference call will also be available in North America by dialing +1 (877) 407-9210 or internationally by dialing +1 (201) 689-8049.
An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, using replay account code # 286 and conference ID # 355460. An archived replay of the conference webcast will also be available on investor relations section of the Skystar corporate website at http://www.skystarbio-pharmaceutical.com.
To be added to the Company’s email distribution for future news releases, please send your request to skystar@grayling.com.
About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.
About Non-GAAP Financial Measures
This press release contains non-GAAP financial measures for the change in the fair value of the Company’s warrants. The Company believes that these non-GAAP financial measures are useful to investors because they exclude non-cash charges that our management excludes when it internally evaluates the performance of the Company’s business and makes operating decisions, including internal budgeting, and performance measurement, because these measures provide a consistent method of comparison to historical periods. Moreover, management believes these non-GAAP measures reflect the essential operating activities of Skystar. Accordingly, management excludes the change in the fair value of the Company’s warrants when making operational decisions. The Company believes that providing the non-GAAP measures that management uses to its investors is useful to investors for a number of reasons. The non-GAAP measures provide a consistent basis for investors to understand the Company’s financial performance in comparison to historical periods. In addition, it allows investors to evaluate the Company’s performance using the same methodology and information as that used by our management. Non-GAAP measures are subject to inherent limitations because they do not include all of the expenses included under GAAP and because they involve the exercise of judgment of which charges are excluded from the non-GAAP financial measure. However, our management compensates for these limitations by providing the relevant disclosure of the items excluded.
The following table provides the non-GAAP financial measure and the related GAAP measure and provides a reconciliation of the non-GAAP measure to the equivalent GAAP measure.
SKBI- Adjusted Net Income
For the Three For the Three
Months Ending Months Ending
June 30, 2010 June 30, 2009
------------- -------------
GAAP Net Income $ 2,378,395 $ (116,797)
GAAP Basic Earnings Per Share 0.33 (0.03)
GAAP Diluted Earnings Per Share 0.33 (0.03)
Additions
Change in fair value of warrants (158,054) 1,480,484
------------- -------------
Addition (subtraction) (158,054) 1,480,484
Non GAAP Net Income $ 2,220,341 $ 1,363,687
Non GAAP Basic Earnings Per Share 0.31 0.36
Non GAAP Diluted Earnings Per Share 0.31 0.36
Shares used in computing net income per basic
share 7,104,606 3,739,024
Shares used in computing net income per diluted
share 7,140,518 3,739,024
SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATION AND OTHER COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
For Three Months Ended For Six Months Ended
June 30, June 30,
------------------------ ------------------------
2010 2009 2010 2009
----------- ----------- ----------- -----------
REVENUE, NET $ 8,264,541 $ 6,243,438 $13,133,784 $10,067,004
COST OF REVENUE 3,905,063 2,958,837 6,196,282 4,905,195
----------- ----------- ----------- -----------
GROSS PROFIT 4,359,478 3,284,601 6,937,502 5,161,809
----------- ----------- ----------- -----------
OPERATING EXPENSES:
Research and
development 192,088 366,695 236,083 484,047
Selling expenses 431,810 585,207 602,944 792,602
General and
administrative 998,034 625,359 1,617,584 940,054
----------- ----------- ----------- -----------
Total operating
expenses 1,621,932 1,577,261 2,456,611 2,216,703
----------- ----------- ----------- -----------
INCOME FROM OPERATIONS 2,737,546 1,707,340 4,480,891 2,945,106
----------- ----------- ----------- -----------
OTHER INCOME (EXPENSE):
Other income
(expense), net 36,257 (310) 36,674 (542)
Interest income
(expense), net (12,976) (788) (17,792) (486)
Change in fair value
of warrant liability 158,054 (1,480,484) (159,326) (1,442,156)
----------- ----------- ----------- -----------
Total other income
(expense), net 181,335 (1,481,582) (140,444) (1,443,184)
----------- ----------- ----------- -----------
INCOME BEFORE PROVISION
FOR INCOME TAXES 2,918,881 225,758 4,340,447 1,501,922
PROVISION FOR INCOME
TAXES 540,486 342,555 865,805 554,075
----------- ----------- ----------- -----------
NET INCOME (LOSS) 2,378,395 (116,797) 3,474,642 947,847
OTHER COMPREHENSIVE
INCOME (LOSS):
Foreign currency
translation
adjustment 280,998 (16,233) 240,182 (54,681)
----------- ----------- ----------- -----------
COMPREHENSIVE INCOME
(LOSS) $ 2,659,393 $ (133,030) $ 3,714,824 $ 893,166
=========== =========== =========== ===========
EARNINGS PER SHARE:
Basic $ 0.33 $ (0.03) $ 0.49 $ 0.25
=========== =========== =========== ===========
Diluted $ 0.33 $ (0.03) $ 0.49 $ 0.25
=========== =========== =========== ===========
WEIGHTED AVERAGE NUMBER
OF COMMON SHARES:
Basic 7,104,606 3,739,024 7,083,149 3,737,708
=========== =========== =========== ===========
Diluted 7,140,518 3,739,024 7,119,846 3,824,432
=========== =========== =========== ===========
SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
June 30, December 31,
ASSETS 2010 2009
------------- -------------
Unaudited
-------------
CURRENT ASSETS:
Cash $ 3,482,558 $ 11,699,398
Accounts receivable, net of allowance for
doubtful accounts of $617,955 and $327,857 as
of June 30, 2010 and December 31, 2009,
respectively 7,711,719 4,383,187
Inventories, net of allowance of $263,539 and
$199,460 as of June 30, 2010 and December 31,
2009, respectively 13,318,742 4,074,645
Deposits and prepaid expenses 4,348,910 11,900,314
Other receivables 549,043 490,712
------------- -------------
Total current assets 29,410,972 32,548,256
------------- -------------
PLANT AND EQUIPMENT, NET 11,786,671 8,829,058
CONSTRUCTION-IN-PROGRESS 8,777,066 9,389,120
OTHER ASSETS:
Long-term prepayments 1,341,031 1,173,427
Long-term prepayments for acquisitions 12,376,146 6,806,880
Intangible assets, net 1,790,327 1,860,172
------------- -------------
Total other assets 15,507,504 9,840,479
------------- -------------
Total assets $ 65,482,213 $ 60,606,913
============= =============
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 553,404 $ 297,567
Other payables and accrued expenses 832,816 917,284
Short-term loans - 220,050
Short-term loans from shareholders - 110,025
Deposits from customers 1,632,581 1,275,958
Taxes payable 1,481,748 722,106
Shares to be issued to related parties 372,739 327,374
Due to related parties 137,503 185,024
------------- -------------
Total current liabilities 5,010,791 4,055,388
------------- -------------
OTHER LIABILITIES:
Deferred government grant 1,104,750 1,100,250
Derivative liability 966,082 1,538,686
------------- -------------
Total other liabilities 2,070,832 2,638,936
------------- -------------
Total liabilities 7,081,623 6,694,324
------------- -------------
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Preferred stock, $0.001 par value, 50,000,000
shares authorized, Nil Series "A" shares
authorized as of June 30, 2010 and December
31, 2009 48,000,000 Series "B" shares
authorized, Nil Series "B" shares issued and
outstanding as of June 30, 2010 and December
31, 2009, respectively - -
Common stock, $0.001 par value, 40,000,000
shares authorized, 7,106,705 and 6,989,640
shares issued and outstanding as of June 30,
2010 and December 31, 2009, respectively 7,106 6,989
Paid-in capital 35,353,156 34,580,096
Statutory reserves 3,879,077 3,879,077
Retained earnings 16,049,548 12,574,906
Accumulated other comprehensive income 3,111,703 2,871,521
------------- -------------
Total shareholders' equity 58,400,590 53,912,589
------------- -------------
Total liabilities and shareholders' equity $ 65,482,213 $ 60,606,913
============= =============
SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2010 AND 2009
(UNAUDITED)
Six months ended June 30,
----------------------------
2010 2009
------------- -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 3,474,642 $ 947,847
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation 299,848 225,953
Amortization 77,133 77,070
Bad debt expense 287,561 -
Allowance for slow moving inventories 63,001 -
Common stock issued for services 16,245 30,521
Common stock to be issued to related
parties for compensation 70,367 78,024
Change in fair value of warrant
liability 159,326 1,442,156
Change in operating assets and liabilities
Accounts receivable (3,584,456) (1,412,505)
Inventories (9,252,221) (5,164,998)
Deposits and prepaid expenses 7,729,174 2,158,970
Other receivables (56,090) (43,532)
Accounts payable 253,565 (197,071)
Other payables and accrued expenses (88,372) (189,065)
Deposits from customers 349,949 (164,796)
Taxes payable 753,555 2,386,654
------------- -------------
Net cash provided by operating
activities 553,227 175,228
------------- -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Refunds of prepayments for potentital
acquistions - 2,711,545
Proceeds from short-term investments - 43,971
Prepayment for acquisitions (5,518,478) -
Loans to third parties - (1,685,555)
Purchases of plant and equipment (2,136,531) -
Payments on construction-in-progress (748,449) (1,792,941)
------------- -------------
Net cash used in investing activities (8,403,458) (722,980)
------------- -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Decrease in restricted cash - 80,662
Proceeds from short-term loans - 205,198
Repayment of short-term loans (220,035) (307,798)
Repayment to shareholders and directors (110,018) -
Proceeds from shareholders and directors - -
Due (from) to related parties (47,874) 420,038
------------- -------------
Net cash (used in) provided by
financing activities (377,927) 398,100
------------- -------------
EFFECT OF EXCHANGE RATE CHANGES ON CASH 11,318 (16,203)
------------- -------------
DECREASE IN CASH (8,216,840) (165,855)
CASH, beginning of period 11,699,398 576,409
------------- -------------
CASH, end of period $ 3,482,558 $ 410,554
============= =============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION:
Cash paid for interest $ 7,435 $ 40,448
============= =============
Cash paid for income taxes $ 578,055 $ -
============= =============
Non-cash investing and financing activities
Long-term prepayment transferred to
construction-in-progress $ - $ 1,025,257
============= =============
Long-term prepayment transferred to plant
and equipment $ 439,897 $ -
============= =============
Construction-in-progress transferred to
plant and equipment $ 1,396,211 $ -
============= =============
Interest expense capitalized as
construction-in-progress $ $ 40,050
============= =============
Cashless exercise of warrants $ 1,511,604 $ -
============= =============
Issuance of common stock accrued in
previous year $ 25,002 $ -
------------- -------------
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
TraderPower Featured Companies
- Annovis Bio Inc. (NYSE: ANVS)
- Astrotech Corp. (NASDAQ: ASTC)
- Cepton Inc. (NASDAQ: CPTN)
- Clene Inc. (NASDAQ: CLNN)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)
- Fintech Ecosystem Development Corp. (NASDAQ: FEXD)
- Freight Technologies Inc. (NASDAQ: FRGT)
- InMed Pharmaceuticals Inc. (NASDAQ: INM)
- Lexaria Bioscience Corp. (NASDAQ: LEXX)
- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)
- Mullen Automotive Inc. (NASDAQ: MULN)
- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)
Top Small Cap Market News
- $ANVS Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast
- $SCNI InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
- $INM InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment
- $SFWJ Hemp Industry Says Missouri Governor ‘Overreached’ When Banning Hemp Intoxicants
- $RFHRF InvestorNewsBreaks – Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) (FSE: 9RR) Shares Update on Completed, Upcoming Exploration Activities
- $MUX InvestorNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Closes on Acquisition of Timberline Resources
- $ECGI InvestorNewsBreaks – ECGI Holdings Inc. (ECGI) Says Success of Allon Equestrian Apparel Line at AETA Is ‘Pivotal Moment’
Recent Posts
- $ECGI InvestorNewsBreaks – ECGI Holdings Inc. (ECGI) Says Success of Allon Equestrian Apparel Line at AETA Is ‘Pivotal Moment’
- $MUX InvestorNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Closes on Acquisition of Timberline Resources
- $RFHRF InvestorNewsBreaks – Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) (FSE: 9RR) Shares Update on Completed, Upcoming Exploration Activities
- $SFWJ Hemp Industry Says Missouri Governor ‘Overreached’ When Banning Hemp Intoxicants
- $INM InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment
- $SCNI InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
- $ANVS Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast
- $FLGC CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space
Recent Comments
Archives
- August 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009